DVAX vs RJF · rev $277.2M vs rev $15.91B
Dynavax Technologies Corporation (DVAX) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
RJF (RJF) common stock.
Latest reported DVAX revenue for 2024-12-31 was $277.2M. Net income was $27.3M. Revenue was up 19.4% from 2023-12-31 to 2024-12-31. DVAX currently screens at market cap $1.82B.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
DVAX currently screens at market cap $1.82B. RJF currently screens at market cap $0.
Not investment advice. Open the DVAX and RJF stock pages for the full models.
Not investment advice.